MapLight Therapeutics (MPLT) SEC Filings: History & Chart

MapLight Therapeutics, Inc.(MPLT)

Biotechnology · Redwood City, CA

$9.69+0.41 (+4.47%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Redwood City, CA

133 employees

www.maplightrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher A. Kroeger

View full financials

Form	Filing Date	Accepted	Document
EFFECT	Sep 23, 2026	Sep 24, 2026	View filing
424B3	Sep 23, 2026	Sep 23, 2026	View filing
S-1/A	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
144	Sep 16, 2026	Sep 16, 2026	View filing
S-1	Sep 9, 2026	Sep 9, 2026	View filing
SC 13G	Aug 20, 2026	Aug 20, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 19, 2026	Aug 19, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13D/A	Aug 18, 2026	Aug 18, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
SC 13D/A	Aug 3, 2026	Aug 3, 2026	View filing
144	Aug 3, 2026	Aug 3, 2026	View filing
SC 13D/A	Jul 31, 2026	Jul 31, 2026	View filing
144	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 28, 2026	Jul 28, 2026	View filing
8-K	Jul 27, 2026	Jul 27, 2026	View filing
4	Jul 20, 2026	Jul 20, 2026	View filing
4	Jul 20, 2026	Jul 20, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing
4	Jul 17, 2026	Jul 17, 2026	View filing

SEC Filings

Recent Filings